Shanghai Ziyuan

Shanghai Ziyuan Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, focusing on the discovery and development of innovative small molecule drugs for metabolic diseases and oncology. The company's lead candidate, ZY-022, is an orally available, non-peptide small molecule GLP-1 receptor agonist currently in Phase 2 clinical trials for type 2 diabetes and obesity. Ziyuan Pharmaceutical utilizes its robust medicinal chemistry platform to develop differentiated therapies that offer improved patient convenience and efficacy compared to traditional injectable treatments. The company's pipeline also includes early-stage programs targeting various solid tumors through novel molecular pathways. With a strong emphasis on internal R&D, Shanghai Ziyuan aims to become a leader in the next generation of metabolic and cancer treatments. The firm has successfully raised capital from prominent healthcare investors to accelerate its clinical programs and expand its research capabilities.